Story perspectives

FDA Panel Proposes Rejecting Seven Peptides, Kennedy Advocates Looser Rules

7/23/2026

Summary

Story summary

The Food and Drug Administration (FDA) Pharmacy Compounding Advisory Committee, composed of professionals instead of academics, will meet Thursday-Friday to review seven peptides for addition to 503A Bulks List.
Health and Human Services Secretary Robert F. Kennedy Jr. said he is a fan of peptides and wants looser restrictions.
FDA experts argue evidence is lacking and propose not adding BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax or Epitalon to the list.

1 of 1

Story summary

The Food and Drug Administration (FDA) Pharmacy Compounding Advisory Committee, composed of professionals instead of academics, will meet Thursday-Friday to review seven peptides for addition to 503A Bulks List.
Health and Human Services Secretary Robert F. Kennedy Jr. said he is a fan of peptides and wants looser restrictions.
FDA experts argue evidence is lacking and propose not adding BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax or Epitalon to the list.